Takeda’s top five brands all grew substantially in FY 2022, none by less than 30 percent.
Tag Archive for: Entyvio
Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.
